Extensive review of Ambit Biosciences Corporation’s "entire" oncology pipeline to date.

Extensive review of ARIUS Research Inc’s "entire" oncology pipeline to date.

Extensive review of Aeterna Zentaris Inc.’s "entire" oncology pipeline to date.

Extensive review of AnorMED Inc.’s "entire" oncology pipeline to date.

Extensive review of ArQule Inc’s "entire" oncology pipeline to date.

Extensive review of Alfacell Corporation’s "entire" oncology pipeline to date.

Extensive review of Aphton Corporation’s "entire" oncology pipeline to date.

Extensive review of Adherex Technologies Inc’s "entire" oncology pipeline to date.

Extensive review of Angiogene Pharmaceuticals Ltd’s "entire" oncology pipeline to date.

Extensive review of Agensys Inc’s "entire" oncology pipeline to date.

Extensive review of Antisoma plc’s "entire" oncology pipeline to date.

Extensive review of Abiogen Pharma SpA’s "entire" oncology pipeline to date.

Extensive review of Amgen Inc.’s "entire" oncology pipeline to date.

Extensive review of Affymax Inc’s "entire" oncology pipeline to date.

Extensive review of Antigenics, Inc.’s "entire" oncology pipeline to date.

Extensive review of Abbott Laboratories’s "entire" oncology pipeline to date.

Extensive review of Millennium’s "entire" oncology pipeline to date.

Extensive review of EntreMed’s "entire" oncology pipeline to date.

Extensive review of Titan Pharmaceuticals’s "entire" oncology pipeline to date.

Extensive review of Curacyte’s "entire" oncology pipeline to date.

Extensive review of SkyePharma’s "entire" oncology pipeline to date.

Extensive review of Maxim’s "entire" oncology pipeline to date.

Extensive review of Cancer Research Technology’s "entire" oncology pipeline to date.

Extensive review of Sanofi-Aventis’s "entire" oncology pipeline to date.

Extensive review of Ipsen’s "entire" oncology pipeline to date.

Extensive review of Pharmexa’s "entire" oncology pipeline to date.

Extensive review of Immuno-Designed Molecules’s "entire" oncology pipeline to date.

Extensive review of AstraZeneca’s "entire" oncology pipeline to date.

Extensive review of Novartis International AG’s "entire" oncology pipeline to date.

Extensive review of Genzyme’s "entire" oncology pipeline to date.